Completed PHASE4 INTERVENTIONAL 2-arm NCT04023227

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC (PARACHUTE-HF)

A Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint, Phase 4 Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With Chronic Chagas' Cardiomyopathy. The Study is Also Know as Prevention And Reduction of Adverse Outcomes in Chagasic Heart failUre Trial Evaluation (PARACHUTE-HF).

Sponsor: Novartis Pharmaceuticals

Conditions Chagas Disease Heart Failure

Interventions Enalapril Sacubitril/valsartan

Updated 28 times since 2019 Last updated: Nov 18, 2025 Started: Dec 10, 2019 Primary completion: Mar 16, 2025 Completion: Mar 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04023227, this PHASE4 trial focuses on Chagas Disease and Heart Failure and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 28 times since 2019, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

28 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE4
Sep 2025 — Dec 2025 [monthly]

Completed PHASE4
Jun 2025 — Sep 2025 [monthly]

Completed PHASE4
May 2025 — Jun 2025 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Apr 2025 — May 2025 [monthly]

Active Not Recruiting PHASE4

▶ Show 23 earlier versions

Jan 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE4
Nov 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE4
Oct 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE4
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE4
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE4
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE4
Dec 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE4
Nov 2023 — Dec 2023 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE4
May 2023 — Oct 2023 [monthly]

Recruiting PHASE4
Mar 2023 — May 2023 [monthly]

Recruiting PHASE4
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE4
Dec 2022 — Feb 2023 [monthly]

Recruiting PHASE4
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE4
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE4
Jan 2022 — Sep 2022 [monthly]

Recruiting PHASE4
May 2021 — Jan 2022 [monthly]

Recruiting PHASE4
Jan 2021 — May 2021 [monthly]

Recruiting PHASE4
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE4
Aug 2020 — Dec 2020 [monthly]

Recruiting PHASE4

Status: Suspended → Recruiting
May 2020 — Aug 2020 [monthly]

Suspended PHASE4

Status: Recruiting → Suspended
Apr 2020 — May 2020 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Aug 2019 — Apr 2020 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Belo Horizonte, Brazil , Belém, Brazil , Bogota, Colombia , Bogota DC, Colombia , Botucatu, Brazil , Bragança Paulista, Brazil , Brasila, Brazil , Brasília, Brazil , Buenos Aires, Argentina , CABA, Argentina and 45 more locations